Fibroblast Growth Factor 2's role in Fear and Approach Motivation in Anxious and Depressed Children and their Mothers

项目摘要 这是一个探索性/发展性的研究建议，旨在建立和扩大 成纤维细胞生长因子2（FGF 2）在恐惧（急性威胁）和方法中的作用 动机是负价系统和正价系统中的两个结构， NIMH Research Domain Criteria（RDoC）项目。FGF 2是一个家族， 影响神经发育并在整个过程中发挥神经调节作用的生长因子 生命，塑造有机体对环境的反应。负原子价的破坏 和正价系统表征焦虑和抑郁障碍，这解释了 大多数精神残疾的人。动物和稀疏的成年人 在焦虑和抑郁模型中涉及FGF 2的研究导致将FGF 2纳入RDoC 作为分析恐惧结构的目标生物单位。据我们所知， 研究了患有焦虑症及其疾病的人的FGF 2，我们也不知道有一项研究， 在临床和非临床儿科样本中检查了FGF 2，焦虑和/或抑郁。我们 研究小组收集了50名焦虑和抑郁患者的临床样本中FGF 2水平的初步数据， 孩子和他们的母亲除了自我报告和行为数据，对应于 恐惧和接近动机。我们研究了FGF 2与肿瘤发生的关系。 水平，自我报告和行为的儿童和母亲，并发现显着的关联 在测量单元之间以及在预期的方向上。这些数据与 动物和人类研究表明，FGF 2可能在调节恐惧和接近中发挥作用。 动机，这可以导致令人兴奋的，新的研究方向。从那时起，我们积累了 在150名焦虑和/或抑郁的儿童和母亲的血清样本，自我报告， 行为数据我们要求R21基金进行免疫分析，以测量FGF 2 在这个样本数据中的浓度。我们亦建议扩大抽样范围， 收集代表另外100名儿童的FGF 2、自我报告和行为数据 “正常”对照和亚临床或阈下焦虑和/或抑郁，以及母亲。与 这些累积的维度数据，我们将研究这些测量单位与 恐惧和接近动机的测量模型使用验证性因素分析。我们 最后，探索性的目的是关于FGF 2的稳定性问题，与自我报告有关， 行为

Project Summary This is an exploratory/developmental research proposal which seeks to build on and to enlarge our data into the role of fibroblast growth factor 2 (FGF2) in Fear (Acute Threat) and Approach Motivation, two constructs within the Negative Valence System and Positive Valence System, respectively, in the NIMH Research Domain Criteria (RDoC) project. FGF2 is one of a family of growth factors that impact neural development and that play neuromodulatory roles throughout life, shaping the organism's response to the environment. Disruptions in the Negative Valence and Positive Valence Systems characterize anxiety and depressive disorders, which account for the majority of psychiatric disability over the lifespan. The animal and sparse adult human studies implicating FGF2 in models of anxiety and depression led to FGF2's inclusion in RDoC as a target biological unit of analysis of the Fear construct. We know of no study that has examined FGF2 in humans with anxiety and its disorders, nor do we know of a study that examined FGF2 in clinical and nonclinical pediatric samples, anxious and/or depressed. Our team collected pilot data of FGF2 levels in a clinical sample of 50 anxious and depressed children and their mothers in addition to self-report and behavior data that corresponded with Fear, and Approach Motivation, respectively. We examined the associations between FGF2 levels, self-reports, and behavior in the children and mothers and found significant associations between the measurement units, and in the expected directions. These data, consistent with the animal and human studies, suggest FGF2 may play a role in modulating Fear, and Approach Motivation, which can lead to exciting, new research directions. We have since accumulated serum samples in 150 anxious and/or depressed children and mothers, and self-report and behavior data. We request R21 funds to conduct immunoassay analysis to measure FGF2 concentrations in this sample data. We also propose to broaden our sampling frame by collecting FGF2, self-report, and behavior data on 100 additional children who represent “normal” controls, and subclinical or subthreshold anxiety and/or depression, and mothers. With these cumulative, dimensional data, we will study these measurement units' associations with Fear, and Approach Motivation in a measurement model using confirmatory factor analysis. Our final, exploratory aim is on the question of stability of FGF2, in relation to self-reports and behavior.